Pfizer (PFE) will report first-quarter 2024 results on May 1, before market open.The Zacks Consensus Estimate for the drug giant’s first-quarter revenues stands at $13.86 billion, while the same for earnings per share is pegged at 56 cents, both indicating significant declines from the year-ago quarter.Pfizer’s top-line numbers in the first quarter of 2024 will include revenues from the acquisition of Seagen, which closed in mid-December 2023. The acquisition added Seagen’s antibody-drug conjugates or ADCs ...

Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium includes access to the Zacks Style Scores as well.What are the Zacks Style Scor ...

GERMANY - 2024/02/16: In this photo illustration, a Pfizer, Inc. logo seen displayed on a tablet. ... [+] (Photo Illustration by Igor Golovnov/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty ImagesPfizer (NYSE: PFE) is scheduled to report its Q1 2024 results on Wednesday, May 1. We expect the company to post revenue of $13.8 billion and earnings of $0.50 on a per share and adjusted basis. The company is likely to see a continued decline in sales due to lower demand for its Covid-1 ...

Analysts on Wall Street project that Pfizer (PFE) will announce quarterly earnings of $0.56 per share in its forthcoming report, representing a decline of 54.5% year over year. Revenues are projected to reach $13.86 billion, declining 24.2% from the same quarter last year.Over the last 30 days, there has been a downward revision of 2.5% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over ...

The Food and Drug Administration on Friday approved Pfizer's treatment for a rare genetic bleeding disorder, making it the company's first-ever gene therapy to win clearance in the U.S. The agency greenlit the drug, which will be marketed as Beqvez, for adults with moderate to severe hemophilia B who meet certain requirements.More than 7,000 people in the U.S. are living with the debilitating condition, according to an advocacy group. The condition is caused by insufficient levels of a certain protein that ...

These two pharma stocks have followed distinct paths of late. Which is the better investment?The pharmaceutical industry has been a whirlwind of highs and lows for investors over the past two decades. The high-risk, high-reward nature of drug development, coupled with the cyclical pattern of new drug launches and patent expirations, has seemingly lost its allure for many investors over the past 20 years.However, amid this challenging landscape, some early stage biotech firms have still managed to deliver li ...

Pfizer (PFE) closed at $26.26 in the latest trading session, marking a +1% move from the prior day. This move outpaced the S&P 500's daily gain of 0.87%. Elsewhere, the Dow gained 0.67%, while the tech-heavy Nasdaq added 1.11%.Coming into today, shares of the drugmaker had lost 4.97% in the past month. In that same time, the Medical sector lost 6.67%, while the S&P 500 lost 3.97%.The investment community will be closely monitoring the performance of Pfizer in its forthcoming earnings report. The company is ...

CatEyePerspectiveIntroduction: A biotech stock with a large dividend is pretty uncommon since biotechnology and pharmaceutical companies tend to focus more on reinvestment into pipeline growth rather than shareholder returns. But as a biopharma grows larger and there may be a paucity of potential pipeline or partnership opportunities that may be worth investing in, the company may look to return some of its profits to its investors through either dividends or share repurchases. Pfizer (NYSE:PFE) seems t ...

Pfizer (PFE) closed the latest trading day at $25.91, indicating a +0.19% change from the previous session's end. The stock outperformed the S&P 500, which registered a daily loss of 1.2%. Elsewhere, the Dow saw a downswing of 0.65%, while the tech-heavy Nasdaq depreciated by 1.79%.Heading into today, shares of the drugmaker had lost 7.44% over the past month, lagging the Medical sector's loss of 6.57% and the S&P 500's loss of 0.85% in that time.The investment community will be paying close attention to th ...

The pharmaceutical giant is laying the groundwork for its next heyday.Pfizer (PFE -1.82%) isn't exactly a hot stock right now. Since its massive run-up during the pandemic's height, built on hopes for its coronavirus vaccine, new sources of growth haven't led to equally outsized windfalls.But for investors, it could still be a great pickup once a few of the loftier expectations about its future are safely in check. Let's start by hearing from the bears about why the stock isn't a buy, and then look at the o ...